Special Issue: "New Diagnostic and Therapeutic Tools against Multidrug-Resistant Tumors (STRATAGEM Special Issue, EU-COST CA17104)"

Cancers (Basel). 2022 Nov 8;14(22):5491. doi: 10.3390/cancers14225491.

M Helena Vasconcelos^{1

2

3}, Catherine Passirani⁴, Chiara Riganti^{5

6}

¹ i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal.
² IPATIMUP-Institute of Molecular Pathology and Immunology, University of Porto, Rua Júlio Amaral de Carvalho 45, 4200-135 Porto, Portugal.
³ Department of Biological Sciences, FFUP-Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.
⁴ Micro et Nanomédecines Translationnelles, MINT, UNIV Angers, UMR INSERM 1066, UMR CNRS 6021, SFR ICAT, 49000 Angers, France.
⁵ Department of Oncology, University of Torino, Via Santena 5/bis, 10126 Torino, Italy.
⁶ Interdepartmental Research Center for Molecular Biotechnology "G. Tarone", University of Torino, Via Nizza 52, 10126 Torino, Italy.

Abstract

Cancer drug resistance, either intrinsic or acquired, often causes treatment failure and increased mortality [...].

This article is based upon work from COST Action CA17104 STRATAGEM, supported by COST (European Cooperation in Science and Technology) (www.cost.eu).